

Glenmark bags FDA approval for Lidocaine Ointment

12 September 2016 | News | By BioSpectrum Bureau

Glenmark bags FDA approval for Lidocaine Ointment



Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Lidocaine Ointment USP, 5%, the generic version of Xylocaine Ointment, 5% of AstraZeneca.

According to IMS Health sales data for the 12 month period ending July 2016, the Xylocaine Ointment, 5% market achieved annual sales of approximately \$373.0 million.

[Also read: Global coalition CEPI formed to tackle infectious diseases](#)

Glenmark's current portfolio consists of 109 products authorized for distribution in the U.S. marketplace and 62 ANDA's pending approval with the U.S. FDA.